CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of nonmelanoma skin cancer.
  
  LEARNING OBJECTIVES

  • Formulate a long-term clinical plan for the management of locally advanced or metastatic basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
  • Use available clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the care of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).
  • Evaluate available clinical research findings with targeted and immunotherapeutic agents as neoadjuvant or adjuvant therapy for patients with cSCC and BCC to determine the current and potential clinical utility of these approaches.
  • Recall the rationale for and design of ongoing clinical trials evaluating novel agents and strategies for cSCC and BCC, and appropriately counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Nikhil I Khushalani, MD
  Senior Member and Vice Chair
  Department of Cutaneous Oncology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: Bristol Myers Squibb, Castle Biosciences Incorporated, Genzyme Corporation, Instil Bio, Iovance Biotherapeutics, Merck, Nektar, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Contracted Research: Bristol Myers Squibb, Celgene Corporation, GSK, HUYA Bioscience International, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Incyte Corporation; Stock Options/Ownership — Public Company: Amarin Corporation, Asensus Surgical, Bellicum Pharmaceuticals Inc; Study Steering Committee: Bristol Myers Squibb, Nektar, Regeneron Pharmaceuticals Inc, Replimune; Travel Remuneration: Regeneron Pharmaceuticals Inc.
  
  Anna C Pavlick, DO, MBA
  Professor of Medicine
  Division of Hematology and Medical Oncology
  Associate Director for Clinical Research
  Weill Cornell Medicine Meyer Cancer Center
  Founding Director of the Cutaneous Oncology Program
  Weill Cornell Medicine and NewYork-Presbyterian
  New York, New York
  
  Advisory Committee: Bristol Myers Squibb, Regeneron Pharmaceuticals Inc, Replimune; Consulting Agreements: Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals Inc, Replimune; Contracted Research: Merck, Replimune.
  
  SURVEY PARTICIPANTS — Omid Hamid, MD — Advisory Committee and Consulting Agreements: Alkermes, Amgen Inc, Bactonix, BeiGene Ltd, BioAtla, Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Georgiamune, GigaGen, GSK, Grit Bio, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Instil Bio, IO Biotech, Iovance Biotherapeutics, Janssen Biotech Inc, KSQ Therapeutics, Merck, Moderna, Novartis, Obsidian Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Tempus, Zelluna Immunotherapy AS; Contracted Research: Akeso Inc, Amgen Inc, Arcus Biosciences, BioAtla, Bristol Myers Squibb, Chinook Therapeutics, CytomX Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Iovance Biotherapeutics, Merck, Merck Serono, Moderna, NextCure, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Seagen Inc, Zelluna Immunotherapy AS; Speakers Bureau: Bristol Myers Squibb, Immunocore, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationship: Vial. Evan J Lipson, MD — Advisory Committee: Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck; Consulting Agreements: CareDx, Eisai Inc, HUYA Bioscience International, Immunocore, Instil Bio, Merck KGaA, Natera Inc, Nektar, Novartis, OncoSec Medical, Pfizer Inc, Rain Oncology, Regeneron Pharmaceuticals Inc, Replimune, Sanofi; Contracted Research: Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals Inc, Sanofi. Sunil Arani Reddy, MD — No relevant conflicts of interest to disclose. Jeffrey S Weber, MD, PhD — Advisory Board: Bristol Myers Squibb; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biond Biologics, Celldex Therapeutics, EMD Serono Inc, Evaxion Biotech A/S, Genentech, a member of the Roche Group, GSK, ImCheck Therapeutics, Incyte Corporation, Merck, Moderna, Nektar, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, SELLAS Life Sciences; Equity (Options): Biond Biologics, OncoC4; Patents: Moffitt Cancer Center filed a patent on an ipilimumab biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on; Research Support to Institution: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Merck, Moderna, Novartis, Pfizer Inc; Scientific Advisory Board: Biond Biologics, CytomX Therapeutics, ImCheck Therapeutics, Incyte Corporation, Instil Bio, NexImmune, OncoC4, SELLAS Life Sciences.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Regeneron Pharmaceuticals Inc.
  
  Release date: October 2023
  Expiration date: October 2024